Opinion

Douglas Flora

Aug 24, 2025, 12:33

Douglas Flora: Promise of MRD Testing in GI Cancers

Douglas Flora, President-Elect Association of Cancer Care Centers at Association of Cancer Care Centers, shared on LinkedIn:

“What if we could spot a cancer relapse months before it shows up on a scan? That’s the promise of molecular residual disease (MRD) testing in GI cancers.

Upcoming Webinar

Target, Track, Treat: Optimizing GI Cancer Management with MRD Testing

Gastrointestinal cancers remain among the most deadly worldwide. In the U.S. alone, projections for 2025 show ~30,000 new cases and more than 10,000 deaths. One of the major challenges? Tiny fragments of cancer that linger after treatment – too small to be seen on conventional scans, but still capable of fueling relapse.

That’s where circulating tumor DNA (ctDNA) testing for MRD comes in, giving us a clearer view of cancer that might otherwise remain hidden.

I’m looking forward to joining esteemed GI Oncologist, Dr. Midhun Malla for this important discussion hosted by AI in Precision Oncology. Together, we’ll explore:

How MRD testing sharpens risk stratification and treatment pathways
The latest evidence for MRD as a predictive biomarker across GI cancers
Practical strategies to integrate MRD into everyday oncology practice

This webinar is part of our AI in Precision Oncology series – bringing together experts to share the latest evidence, real-world applications, and practical steps for making cancer care more precise, more personal, and more effective.

Wednesday, September 10, 2025
4:00 pm ET | 1:00 pm PT | 22:00 CET”

More posts featuring Douglas Flora.